Breaking news: Cipla succeeds in revoking Pfizer / Sugen’s patent on Sunitinib
The Patent Office in a recent post grant opposition proceeding brought by Cipla against Pfizer / Sugen’s patent on the drug Sunitinib, revoked Indian patent IN209251. The drug Sunitinib is used to treat diseases caused by abnormal protein kinase activity. Interestingly the patent was revoked primarily on the ground that it lacked an inventive step (Section 2(1)(j)). Pfizer / Sugen had earlier succeeded in defending a compulsory license (CL) proceeding earlier for the same patent. The CL proceeding was withdrawn by […]
Breaking news: Cipla succeeds in revoking Pfizer / Sugen’s patent on Sunitinib Read More »